Skip Navigation
Search Menu
Find a Doctor

 

Photo of Dr. Hans Hammers

Hans Joerg Hammers, M.D., Ph.D.

Assistant Professor of Oncology

Male  | Languages: English, German

Appointment Phone

410-955-8964

Main Location

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-7683 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Assistant Professor of Oncology

Centers & Institutes

Departments

  • Oncology - Prostate Cancer and GU

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964

401 N. Broadway
Baltimore, MD 21231 map

The Johns Hopkins Hospital

Appointment Phone: 410-955-8964

600 N. Wolfe Street
Sheikh Zayed Tower
Baltimore, MD 21287 map

The Johns Hopkins Hospital

600 N. Wolfe Street
Carnegie 446D1
Baltimore, MD 21287 map

Expertise

Bladder Cancer, Kidney Cancer, Medical Oncology, Prostate Cancer, Testicular Cancer

Research Interests

KIdney Cancer; Angiogenesis; Immunotherapy; Prostate cancer

    Additional Information

  • Education +

    Degrees

    • University of Lubeck / MD (1999)

    Residencies

    • Johns Hopkins Bayview Medical Center / Medicine (2005)

    Fellowships

    • Johns Hopkins University School of Medicine / Medical Oncology (2009)

    Certifications

    • American Board of Internal Medicine / Internal Medicine (2007)
    • American Board of Internal Medicine / Medical Oncology (2011)
  • Research & Publications +

    Selected Publications

    Stebbing, J.; Wood, C.; Atkins, M.; Bukowski, R.; Litwin, S.; Bower, M.; Parsa, A.; Levitsky, H. Cancer vaccines: clinical development challenges and proposed regulatory approaches for patient access to promising treatments. Cancer. 2008 Mar 1;112(5):955-961.

    Verheul, H.M.; Salumbides, B.; Van Erp, K.; Hammers, H.; Qian, D.Z.; Sanni, T.; Atadja, P.; Pili, R. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res. 2008 Jun 1;14(11):3589-3597.

    Zhang, H.; Qian, D.Z.; Tan, Y.S.; Lee, K.; Gao, P.; Ren, Y.R.; Rey, S.; Hammers, H.; Chang, D.; Pili, R.; Dang, C.V.; Liu, J.O.; Semenza, G.L. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19579-19586.

    Ellis, L.; Hammers, H.; Pili, R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett. 2009 Aug 8;280(2):145-153.

    Georgiades, C.S.; Rodriguez, R.; Littrup, P.J.; Frangakis, C.E.; Leveille, R.; Ahrar, K.; Atwell, T.D.; Cadeddu, J.; Trimmer, C.; Durack, J.C.; Hammers, H.J.; Meng, M.V.; Raman, S.; Solomon, S.B.; Zagoria, R.J.; McLennan, G.; Laberge, J.M.; Gervais, D.A.; Kee, S.T. Development of a research agenda for percutaneous renal tumor ablation: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol. 2010 Dec;21(12):1807-1816.

    Hammers, H.J.; Verheul, H.M.; Salumbides, B.; Sharma, R.; Rudek, M.; Jaspers, J.; Shah, P.; Ellis, L.; Shen, L.; Paesante, S.; Dykema, K.; Furge, K.; Teh, B.T.; Netto, G.; Pili, R. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther. 2010 Jun;9(6):1525-1535.

    Kachhap, S.K.; Rosmus, N.; Collis, S.J.; Kortenhorst, M.S.; Wissing, M.D.; Hedayati, M.; Shabbeer, S.; Mendonca, J.; Deangelis, J.; Marchionni, L.; Lin, J.; Hoti, N.; Nortier, J.W.; DeWeese, T.L.; Hammers, H.; Carducci, M.A. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One. 2010;5(6):e11208.

    Koskimaki, J.E.; Karagiannis, E.D.; Tang, B.C.; Hammers, H.; Watkins, D.N.; Pili, R.; Popel, A.S. Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model. BMC Cancer. 2010;10:29.
  • Academic Affiliations & Courses +
  • Activities & Honors +
  • Videos & Media +
Is This You? Edit Profile